Short Interest in Oculis Holding AG (NASDAQ:OCS) Decreases By 65.2%

Oculis Holding AG (NASDAQ:OCS) saw a large decline in short interest in October. As of October 31st, there was short interest totalling 15,700 shares, a decline of 65.2% from the October 15th total of 45,100 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 47,400 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Oculis in a research report on Monday. Five analysts have rated the stock with a buy rating, According to MarketBeat, Oculis has a consensus rating of “Buy” and a consensus target price of $29.20.

Oculis Price Performance

NASDAQ OCS traded down $0.20 during mid-day trading on Wednesday, hitting $14.79. The company’s stock had a trading volume of 43,412 shares, compared to its average volume of 36,888. The company has a current ratio of 4.02, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. Oculis has a 52-week low of $9.60 and a 52-week high of $18.00. The stock’s fifty day simple moving average is $14.15 and its two-hundred day simple moving average is $12.66.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Equities research analysts anticipate that Oculis will post -2.1 earnings per share for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.